Merck & Co., Inc.
NYSE:MRKDrug Manufacturers - General
-$1.32 today
- Market cap
- $339.66B
- Beta
- 0.22
- P/E (TTM)
- 31.6
- EPS (TTM)
- $3.61
- Dividend yield
- 2.94%
Volume 9.69M
Average 11.85M
MRK Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Merck & Co., Inc.NYSE: MRK
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities remains negative
Q2 FY2026 other current liabilities was $18.95B, compared with $0 a year earlier.
Context
- Other current liabilities amounted to 14.6% of total assets at the end of Q2 FY2026, up 14.6 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 14.09B USD
- Year-over-year change
- +5096.1%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.09B | +5096.1% |
| FY2024 | 2024-12-31 | (282M) | +1.1% |
| FY2023 | 2023-12-31 | (285M) | -1.4% |
| FY2022 | 2022-12-31 | (281M) | +7.6% |
| FY2021 | 2021-12-31 | (304M) | — |
Other Current Liabilities vs competitors
How MRK compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Other current liabilities amounts to 14.6% of total assets for MRK, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $22.81B USD | -2.8% | -11.0% | 11.3% | |
| Jun 2026 | $18.95B USD | — | — | 14.6% | |
| Jun 2026 | $15.32B USD | -3.1% | +4.6% | 12.6% | |
| Jun 2026 | $11.66B USD | +82.7% | +93.3% | 8.2% | |
| Jun 2026 | $3.7B USD | +3.2% | +2.2% | 7.5% | |
| Sep 2026 | $678.8M USD | -42.3% | -64.2% | 0.6% | |
| Jun 2026 | €197M EUR | -98.6% | +7.4% | 0.2% | |
| Jun 2026 | $128M USD | -69.0% | +7.0% | 0.1% | |
| Sep 2026 | $0 USD | -100.0% | -11.9% | 0.0% | |
| Jun 2026 | $0 USD | — | +9.4% | 0.0% | |
| Peer median (excluding MRK) | — | -22.7% | +4.6% | 0.6% | |
Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.1B | 12.69B | 6.84B | 13.24B | 14.57B |
| Short-term Investments | 0 | 498M | 252M | 447M | 0 |
| Net Receivables | 9.23B | 9.45B | 10.35B | 10.28B | 12.68B |
| Inventory | 5.95B | 5.91B | 6.36B | 6.11B | 6.66B |
| Other Current Assets | 6.99B | 7.17B | 8.37B | 8.71B | 9.49B |
| Total Current Assets | 30.27B | 35.72B | 32.17B | 38.78B | 43.52B |
| Property, Plant & Equipment (Net) | 19.28B | 21.42B | 23.05B | 23.78B | 26.82B |
| Goodwill | 21.26B | 21.2B | 21.2B | 21.67B | 21.58B |
| Intangible Assets | 22.93B | 20.27B | 18.01B | 16.37B | 26.68B |
| Long-term Investments | 370M | 1.02B | 252M | 463M | 2.24B |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 11.58B | 9.53B | 12B | 16.04B | 16.03B |
| Total Non-current Assets | 75.43B | 73.44B | 74.51B | 78.32B | 93.35B |
| Total Assets | 105.69B | 109.16B | 106.68B | 117.11B | 136.87B |
| Account Payables | 4.61B | 4.26B | 3.92B | 4.08B | 4.4B |
| Short-term Debt | 2.41B | 1.95B | 1.37B | 2.65B | 2.88B |
| Tax Payables | 1.22B | 1.99B | 2.65B | 3.91B | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | (304M) | (281M) | (285M) | (282M) | 14.09B |
| Total Current Liabilities | 23.87B | 24.24B | 25.69B | 28.42B | 28.33B |
| Long-term Debt | 30.69B | 28.75B | 33.68B | 34.46B | 46.75B |
| Deferred Tax Liabilities | 3.44B | 1.8B | 871M | 1.39B | 1.44B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 8.21B | 7.31B | 7.86B | 5.59B | 6.79B |
| Total Non-current Liabilities | 43.57B | 38.86B | 43.35B | 42.31B | 55.88B |
| Total Liabilities | 67.44B | 63.1B | 69.04B | 70.73B | 84.2B |
| Common Stock | 1.79B | 1.79B | 1.79B | 1.79B | 1.79B |
| Retained Earnings | 53.7B | 61.08B | 53.9B | 63.07B | 73.08B |
| Accumulated OCI | (4.43B) | (4.77B) | (5.16B) | (4.95B) | (4.29B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 73M | 67M | 54M | 59M | 56M |
| Total Equity | 38.26B | 46.06B | 37.64B | 46.37B | 52.66B |
| Total Debt | 34.63B | 31.99B | 36.27B | 38.27B | 50.53B |
| Net Debt | 26.54B | 19.29B | 29.43B | 25.03B | 35.97B |
Merck & Co., Inc.
NYSE:MRK
Intrinsic Alpha fair value
Locked
Current Price
$137.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.